Developing cell-based therapies for pancreatic ductal adenocarcinoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40231460.
- Also identified by DOI 10.1172/JCI189513 and PMC identifier 11996857.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Prostate stem cell antigen (PSCA) is highly and preferentially expressed on the surface of pancreatic ductal adenocarcinoma (PDAC) cells, raising the promise of tumor-selective cell-based immunotherapies. In this issue of the JCI, Dai et al. harness PSCA for the development of an off-the-shelf chimeric antigen receptor (CAR) invariant natural killer T (iNKT) cell-based treatment for PDAC. Through in vitro experiments and in vivo models, the authors demonstrate selectivity and therapeutic efficacy of PSCA CAR_sIL15 iNKT cells against both gemcitabine-sensitive and -resistant PDAC cells with comparable antitumor activity for freshly produced and frozen off-the-shelf PSCA CAR_sIL15 iNKT cells. This development opens another potential therapeutic option for pancreatic cancer.
Medical subject headings
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms
- Antigens, Neoplasm
- Neoplasm Proteins
- Natural Killer T-Cells
- Immunotherapy, Adoptive